Standardized Definition of Progression Independent of Relapse Activity (Pira) in Relapsing-Remitting Multiple Sclerosis

dc.contributor.author Muller, Jannis
dc.contributor.author Sharmin, Sifat
dc.contributor.author Lorscheider, Johannes
dc.contributor.author Ozakbas, Serkan
dc.contributor.author Karabudak, Rana
dc.contributor.author Horakova, Dana
dc.contributor.author Kalincik, Tomas
dc.date.accessioned 2025-05-25T19:24:27Z
dc.date.available 2025-05-25T19:24:27Z
dc.date.issued 2025
dc.description Lugaresi, Alessandra/0000-0003-2902-5589; Foschi, Matteo/0000-0002-0321-7155 en_US
dc.description.abstract Importance Progression independent of relapse activity (PIRA) is a significant contributor to long-term disability accumulation in relapsing-remitting multiple sclerosis (MS). Prior studies have used varying PIRA definitions, hampering the comparability of study results. Objective To compare various definitions of PIRA. Design, Setting, and Participants This cohort study involved a retrospective analysis of prospectively collected data from the MSBase registry from July 2004 to July 2023. The participants were patients with MS from 186 centers across 43 countries who had clinically definite relapsing-remitting MS, a complete minimal dataset, and 3 or more documented Expanded Disability Status Scale (EDSS) assessments. Exposure Three-hundred sixty definitions of PIRA as combinations of the following criteria: baseline disability (fixed baseline with re-baselining after PIRA, or plus re-baselining after relapses, or plus re-baselining after improvements), minimum confirmation period (6, 12, or 24 months), confirmation magnitude (EDSS score at/above worsening score or at/above threshold compared with baseline), freedom from relapse at EDSS score worsening (90 days prior, 90 days prior and 30 days after, 180 days prior and after, since previous EDSS assessment, or since baseline), and freedom from relapse at confirmation (30 days prior, 90 days prior, 30 days before and after, or between worsening and confirmation). Main Outcome and Measure For each definition, we quantified PIRA incidence and persistence (ie, absence of a 3-month confirmed EDSS improvement over >= 5 years). Results Among 87 239 patients with MS, 33 303 patients fulfilled the inclusion criteria; 24 152 (72.5%) were female and 9151 (27.5%) were male. At the first visits, the mean (SD) age was 36.4 (10.9) years; 28 052 patients (84.2%) had relapsing-remitting MS, and the median (IQR) EDSS score was 2.0 (1.0-3.0). Participants had a mean (SD) 15.1 (11.9) visits over 8.9 (5.2) years. PIRA incidence ranged from 0.141 to 0.658 events per decade and persistence from 0.753 to 0.919, depending on the definition. In particular, the baseline and confirmation period influenced PIRA detection. The following definition yielded balanced incidence and persistence: a significant disability worsening compared with a baseline (reset after each PIRA event, relapse, and EDSS score improvement), in absence of relapses since the last EDSS assessment, confirmed with EDSS scores (not preceded by relapses within 30 days) that remained above the worsening threshold for at least 12 months. Conclusion and Relevance Incidence and persistence of PIRA are determined by the definition used. The proposed standardized definition aims to enhance comparability among studies. en_US
dc.description.sponsorship Swiss Science Foundation [P500PM_214230, P5R5PM_225288]; National Health and Medical Research Council Investigator grants [2026836, 2033165]; MS Australia; Biogen; Novartis; Merck; Roche; Teva; Sanofi Genzyme en_US
dc.description.sponsorship The work was supported by grants from the Swiss Science Foundation (P500PM_214230 and P5R5PM_225288 to Dr Mueller) and by National Health and Medical Research Council Investigator grants (2026836 to Dr Kalincik and 2033165 to Dr Roos). Dr Roos is supported by a MS Australia postdoctora lfellowship grant. The MS Base Foundation is anot-for-profit organization that receives support from Biogen, Novartis, Merck, Roche, Teva,and Sanofi Genzyme en_US
dc.identifier.doi 10.1001/jamaneurol.2025.0495
dc.identifier.issn 2168-6149
dc.identifier.issn 2168-6157
dc.identifier.scopus 2-s2.0-105002792941
dc.identifier.uri https://doi.org/10.1001/jamaneurol.2025.0495
dc.identifier.uri https://hdl.handle.net/20.500.14365/6191
dc.language.iso en en_US
dc.publisher Amer Medical Assoc en_US
dc.relation.ispartof JAMA Neurology
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.title Standardized Definition of Progression Independent of Relapse Activity (Pira) in Relapsing-Remitting Multiple Sclerosis en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.id Lugaresi, Alessandra/0000-0003-2902-5589
gdc.author.id Foschi, Matteo/0000-0002-0321-7155
gdc.author.scopusid 56900313000
gdc.author.scopusid 55028512500
gdc.author.scopusid 54397364000
gdc.author.scopusid 6602895100
gdc.author.scopusid 6602766721
gdc.author.scopusid 55053678000
gdc.author.scopusid 6602736963
gdc.author.wosid Sá, Maria/Agt-9846-2022
gdc.author.wosid Soysal, Aysun/Aax-7696-2021
gdc.author.wosid Horakova, Dana/D-4649-2011
gdc.author.wosid Shaygannejad, Vahid/N-3495-2018
gdc.author.wosid Ozakbas, Serkan/V-6427-2019
gdc.author.wosid Roos, Izanne/Abo-3767-2022
gdc.author.wosid Lugaresi, Alessandra/C-7743-2012
gdc.bip.impulseclass C4
gdc.bip.influenceclass C4
gdc.bip.popularityclass C4
gdc.coar.access metadata only access
gdc.coar.type text::journal::journal article
gdc.collaboration.industrial false
gdc.description.department İzmir Ekonomi Üniversitesi en_US
gdc.description.departmenttemp [Muller, Jannis; Sharmin, Sifat; Roos, Izanne; Kalincik, Tomas] Univ Melbourne, Dept Med, CORe, Melbourne, Vic, Australia; [Muller, Jannis; Sharmin, Sifat; Roos, Izanne; Kalincik, Tomas] Royal Melbourne Hosp, Neuroimmunol Ctr, Dept Neurol, Melbourne, Vic, Australia; [Muller, Jannis; Lorscheider, Johannes; Benkert, Pascal; Kuhle, Jens; Kappos, Ludwig] Univ Hosp Basel, Res Ctr Clin Neuroimmunol & Neurosci Basel RC2NB, Basel, Switzerland; [Muller, Jannis; Lorscheider, Johannes; Benkert, Pascal; Kuhle, Jens; Kappos, Ludwig] Univ Hosp Basel, MS Ctr, Neurol Clin & Policlin, Basel, Switzerland; [Muller, Jannis; Lorscheider, Johannes; Benkert, Pascal; Kuhle, Jens; Kappos, Ludwig] Univ Basel, Basel, Switzerland; [Ozakbas, Serkan] Izmir Univ Econ, Med Point Hosp, Izmir, Turkiye; [Ozakbas, Serkan] Multiple Sclerosis Res Assoc, Izmir, Turkiye; [Karabudak, Rana] Yeditepe Univ Hosp, Yeditepe Fac Med, Neurol Sci Dept, Neurol Neuroimmunol Unit, Istanbul, Turkiye; [Horakova, Dana] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic; [Horakova, Dana] Charles Univ Prague, Fac Med 1, Ctr Clin Neurosci, Prague, Czech Republic; [Horakova, Dana] Gen Univ Hosp, Prague, Czech Republic; [Weinstock-Guttman, Bianca] Jacobs MS Ctr Treatment & Res, Dept Neurol, Buffalo, NY USA; [Shaygannejad, Vahid] Isfahan Univ Med Sci, Esfahan, Iran; [Etemadifar, Masoud] Dr Etemadifar MS Inst, Neurol, Esfahan, Iran; [Alroughani, Raed] Amiri Hosp, Dept Med, Div Neurol, Sharq, Kuwait; [Patti, Francesco] GF Ingrassia, Dept Med & Surg Sci & Adv Technol, Catania, Italy; [Patti, Francesco] AOU Policlin G Rodol San Marco, UOS Sclerosi Multipla, Catania, Italy; [Eichau, Sara] Hosp Univ Virgen Macarena, Dept Neurol, Seville 41004, Spain; [Prat, Alexandre] CHUM MS Ctr, Montreal, PQ, Canada; [Prat, Alexandre] Univ Montreal, Montreal, PQ, Canada; [Lugaresi, Alessandra] IRCCS Ist Sci Neurol Bologna, Bologna, Italy; [Lugaresi, Alessandra] Univ Bologna, Dipartimento Sci Biomed & Neuromotorie, Bologna, Italy; [Tomassini, Valentina] Univ G dAnnunzio, Inst Adv Biomed Technol ITAB, Dept Neurosci Imaging & Clin Sci, Chieti, Italy; [Kermode, Allan G.] Univ Western Australia, Perron Inst Neurol & Translat Sci, Nedlands, WA, Australia; [Amato, Maria Pia] Univ Florence, Dept NEUROFARBA, Florence, Italy; [Amato, Maria Pia] IRCCS Fdn Don Carlo Gnocchi, Florence, Italy; [Turkoglu, Recai] Haydarpasa Numune Training & Res Hosp, Dept Neurol, Istanbul, Turkiye; [Altintas, Ayse] Koc Univ, Sch Med, Dept Neurol, Istanbul, Turkiye; [Altintas, Ayse] Koc Univ, Koc Univ Res Ctr Translat Med KUTTAM, Istanbul, Turkiye; [Buzzard, Katherine] Box Hill Hosp, Dept Neurosci, Melbourne, Vic, Australia; [Buzzard, Katherine] Monash Univ, Eastern Hlth Clin Sch, Box Hill, Vic, Australia; [Soysal, Aysun] Bakirkoy Educ & Res Hosp Psychiat & Neurol Dis, Istanbul, Turkiye; [van der Walt, Anneke; Butzkueven, Helmut] Alfred Hosp, Dept Neurol, Melbourne, Vic, Australia; [Blanco, Yolanda] Hosp Clin Barcelona, Ctr Neuroimmunol, Serv Neurol, Barcelona, Spain; [Gerlach, Oliver] Acad MS Ctr Zuyd, Zuyderland Med Ctr, Dept Neurol, Sittard Geleen, Netherlands; [Gerlach, Oliver] Maastricht Univ, Med Ctr, Sch Mental Hlth & Neurosci, Dept Neurol, Maastricht, Netherlands; [Khoury, Samia J.] Amer Univ, Beirut Med Ctr, Nehme & Therese Tohme Multiple Sclerosis Ctr, Beirut, Lebanon; [Barnett, Michael] Brain & Mind Ctr, Sydney, NSW, Australia; [John, Nevin] Monash Univ, Sch Clin Sci, Dept Med, Melbourne, Vic, Australia; [John, Nevin] Monash Hlth, Dept Neurol, Clayton, Australia; [Lechner-Scott, Jeannette] Univ Newcastle, Hunter Med Res Inst, Newcastle, NSW, Australia; [Foschi, Matteo] S Maria Croci Hosp Ravenna, MS Ctr, Dept Neurosci, Neurol Unit, Ravenna, Italy; [Surcinelli, Andrea] S Maria Delle Croci Hosp, Dept Diagnost Imaging, AUSL Romagna, Ravenna, Italy; [van Pesch, Vincent] UCLouvain, Dept Neurol, Clin Univ St Luc, Brussels, Belgium; [Prevost, Julie] CSSS St Jerome, St Jerome, PQ, Canada; [Sa, Maria Jose] Ctr Hosp Univ Sao Joao, Dept Neurol, Porto, Portugal; [Maimone, Davide] Azienda Osped Emergenza Cannizzaro, Ctr Sclerosi Multipla, UOC Neurol, Catania, Italy; [D'hooghe, Marie] Natl MS Centrum, Deptt Neurol, Melsbroek, Belgium; [Hughes, Stella] Royal Victoria Hosp, Belfast, North Ireland; [Hodgkinson, Suzanne] Univ New South Wales, Immune Tolerance Lab, Ingham Inst, Sydney, NSW, Australia; [Hodgkinson, Suzanne] Univ New South Wales, Dept Med, Sydney, NSW, Australia; [McGuigan, Chris] St Vincents Univ Hosp, Dublin, Ireland; [Cartechini, Elisabetta] P O Unico Macerata, Neurol Unit, Ast Macerata, Macerata, Italy; [Taylor, Bruce] Royal Hobart Hosp, Hobart, Australia; [Spitaleri, Daniele] Azienda Osped Rilievo Nazl San Giuseppe Moscati Av, Avellino, Italy; [Slee, Mark] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA, Australia; [McCombe, Pamela] Univ Queensland, Dept Neurol, Brisbane, Qld, Australia; [Yamout, Bassem] Neurol Inst, Harley St Med Ctr, Abu Dhabi, U Arab Emirates en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q1
gdc.description.volume 82
gdc.description.woscitationindex Science Citation Index Expanded
gdc.description.wosquality Q1
gdc.identifier.openalex W4409413459
gdc.identifier.pmid 40227706
gdc.identifier.wos WOS:001470351300001
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type PubMed
gdc.oaire.diamondjournal false
gdc.oaire.impulse 13.0
gdc.oaire.influence 3.5466297E-9
gdc.oaire.isgreen true
gdc.oaire.keywords Male
gdc.oaire.keywords Adult
gdc.oaire.keywords Middle Aged
gdc.oaire.keywords sclerosi multipla, progressione
gdc.oaire.keywords Cohort Studies
gdc.oaire.keywords Disability Evaluation
gdc.oaire.keywords Multiple Sclerosis, Relapsing-Remitting
gdc.oaire.keywords Recurrence
gdc.oaire.keywords Disease Progression
gdc.oaire.keywords Humans
gdc.oaire.keywords Female
gdc.oaire.keywords Human medicine
gdc.oaire.keywords Registries
gdc.oaire.keywords Retrospective Studies
gdc.oaire.keywords sclerosi multipla, progressione, biomarcatori
gdc.oaire.popularity 1.1946033E-8
gdc.oaire.publicfunded true
gdc.openalex.collaboration International
gdc.openalex.fwci 33.7431
gdc.openalex.normalizedpercentile 1.0
gdc.openalex.toppercent TOP 1%
gdc.opencitations.count 0
gdc.plumx.crossrefcites 1
gdc.plumx.mendeley 40
gdc.plumx.newscount 2
gdc.plumx.pubmedcites 1
gdc.scopus.citedcount 11
gdc.virtual.author Özakbaş, Serkan
gdc.wos.citedcount 14
relation.isAuthorOfPublication 0750ade3-1d29-450d-8c26-aaa8708d1bb0
relation.isAuthorOfPublication.latestForDiscovery 0750ade3-1d29-450d-8c26-aaa8708d1bb0
relation.isOrgUnitOfPublication 7b4bd652-27ef-4beb-a10e-dddd2d65e0fd
relation.isOrgUnitOfPublication fbc53f3e-d1d3-4168-afd8-e42cd20bddd9
relation.isOrgUnitOfPublication e9e77e3e-bc94-40a7-9b24-b807b2cd0319
relation.isOrgUnitOfPublication.latestForDiscovery 7b4bd652-27ef-4beb-a10e-dddd2d65e0fd

Files